Training Program in Pharmacology

药理学培训计划

• 批准号: 10656570
• 负责人: Donald M Bers
• 金额: $ 41.43万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10656570
• 关键词: Pharmacology; Training Programs

TRAINING PROGRAM IN PHARMACOLOGY ABSTRACT: The overarching goal of this predoctoral Training Program in Pharmacology (TPPh) is to educate next generation of biomedical researchers in the concepts of drug discovery and development, inclusive a clinical perspective. The four focus areas of this TPPh are cardiovascular, neurological, and immunological diseases and cancer. UC Davis is a world leader in drug development with multiple trainers bringing drugs to the clinic (most recently Dr. Rogawski the novel post-partum antidepressant Brexanolone) and biologics including gene therapy vectors with >20 ongoing clinical trials (Director Dr. Nolta). Trainees from Pharmacology & Toxicology, Physiology, Biomedical Engineering and Neuroscience develop expertise in diverse areas. Areas include classic pharmacology & drug target identification with cutting edge methods in biochemistry, structural biology, genomics & proteomics, molecular and cell biology; structural modeling and rational drug design; medicinal chemistry; high & superresolution imaging; electrophysiology; behavioral physiology; engineering of microfluidic and other devices; animal models of disease; novel in vivo whole animal imaging; and translational therapeutics in clinical trials including stem cell and genetic therapies. The TPPh will provide focused and student-tailored small group training in the core principles of pharmacology for non-pharmacology trainees, and enmesh these students with pharmacology students for interdisciplinary group learning in drug development. A related goal is to enable all trainees to communicate and collaborate across the large array of research disciplines they represent. This goal is mainly realized in a highly innovative student-driven, project-oriented course Problem Solving in Pharmacological Sciences, which rejuvenates itself every year based on student initiative and interest. In this way our TPPh produces experts with a variety of backgrounds that can effectively communicate and collaborate with experts from other related disciplines in the increasingly complex realm of drug development. UC Davis grants more bachelors and doctoral degrees in biological sciences than any other U.S. university. It received $961 million in extramural research funding in 2020/21, which places it, as in earlier years, among the top 10 public universities. The 30 training faculty are from 14 departments in 6 colleges, where extensive collaborative interactions already exist. Trainers provide in depth expertise that ranges from identifying novel therapeutic molecular targets and development of therapeutic molecules to clinical drug and stem cell trials at the NIH-funded UC Davis Clinical and Translational Science Center (CTSC) and NIH-designated Cancer Center. Powerful and numerous state- of-the-art core facilities and centers will provide trainees with outstanding research opportunities spanning from Chemistry’s emphasis on pharmaceutical chemistry to unique animal models (internationally recognized mouse biology center, Agricultural & Veterinary Schools, Primate Center).

药理学培训计划 抽象的： 该药理学前培训计划（TPPH）的总体目标是教育下一步 生物医学研究人员在药物发现和开发概念中的产生，包括 临床视角。该TPPH的四个焦点区域是心血管，神经和免疫学 疾病和癌症。加州大学戴维斯（UC Davis）是毒品开发的世界领导者，有多个培训师带毒品 到诊所（最近的新型Partum抗抑郁药brexanolone）和生物制剂（Rogawski） 包括具有> 20个正在进行的临床试验的基因治疗载体（主任Nolta）。来自 药理学和毒理学，生理学，生物医学工程和神经科学发展方面的专业知识 潜水区。区域包括经典的药理学和药物靶标识别，并具有前沿方法 生物化学，结构生物学，基因组学和蛋白质组学，分子和细胞生物学；结构建模和 理性药物设计；药化学；高分辨率成像；电生理学；行为 生理;微流体和其他设备的工程；疾病动物模型；小说整体 动物成像；并在包括干细胞和基因疗法在内的临床试验中翻译治疗。这 TPPH将在药理学核心原理中提供专注和学生量的小组培训 对于非药理学学员，并将这些学生与药理学学生融入跨学科的学生 药物开发中的小组学习。一个相关的目标是使所有受训者能够交流和合作 在他们代表的大量研究学科中。这个目标主要是在高度创新的 学生驱动的，以项目为导向的课程解决药理学的解决问题，恢复活力 每年都基于学生倡议和兴趣。这样，我们的TPPH生产了各种各样的专家 可以有效地与其他相关学科的专家进行沟通和合作的背景 在越来越复杂的药物开发领域。 UC Davis授予更多的单身汉和博士学位 生物科学学位比其他任何美国大学。它收到了9.61亿美元的壁外研究 在2020/21年的资金中，这与早期的十大公立大学一样。 30培训 教师来自6所大学的14个系，那里已经存在广泛的合作互动。 培训师提供深入的专家，从识别新型的热分子靶标和 NIH资助的UC Davis临床的临床药物和干细胞试验的治疗分子开发 以及转化科学中心（CTSC）和NIH指定的癌症中心。强大而众多的国家 - ART核心设施和中心将为受训者提供跨越的出色研究机会 从化学对药物化学的重视到独特的动物模型（国际公认 小鼠生物学中心，灵长类动物中心农业和兽医学校）。